Discover the Potential of Injectable Ferric Carboxymaltose with Wexford
At Wexford Laboratories, we are proud to introduce a new addition to our portfolio: Injectable Ferric Carboxymaltose 50 mg/mL, an effective and efficient treatment for iron deficiency anemia, especially indicated for patients in dialysis programs.
This innovative product offers multiple clinical and economic advantages, positioning it as one of the most competitive solutions in today’s market:
Greater Efficiency and Optimized Dosing
-
Allows for the administration of up to 400% more iron in a single dose compared to iron sucrose.
-
100% of the iron goes directly into the bloodstream, ensuring more effective absorption.
-
Fewer injections and a significant reduction in supplies such as diluents and disposable materials.
Real Savings Without Compromising Quality
-
Wexford has revolutionized the price of this treatment, offering up to a 75% reduction compared to the originator product, while maintaining equivalent quality standards.
-
This improvement in the cost-benefit ratio not only benefits patients, but also healthcare institutions and our commercial partners.
A Growing Market
-
Global sales of Ferric Carboxymaltose exceed $1 billion USD annually, reflecting a growing acceptance and demand worldwide.
Why wait?
With Wexford, the future of iron therapy is within everyone’s reach.
Don’t be the last to follow trends…
Create them!
📩 Contact us for more information on availability, registration, and distribution.
Sources:
-
Ferric carboxymaltose injection: MedlinePlus Medicines. (n.d.)
https://medlineplus.gov/spanish/druginfo/meds/a614037-es.html#:~:text=La%20inyecci%C3%B3n%20de%20carboximaltosa%20f%C3%A9rrica%20pertenece%20a%20una%20clase%20de,pueda%20producir%20m%C3%A1s%20gl%C3%B3bulos%20rojos -
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients | BMC Nephrology
https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-1045-8 -
Efficacy and Cost Effectiveness of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Adult Patients with Iron Deficiency Anemia – ScienceDirect
https://www.sciencedirect.com/science/article/pii/S0006497118707799 -
Vifor Pharma reports sustained growth in 2021 | Business Wire
https://www.businesswire.com/news/home/20220216005976/en/Vifor-Pharma-reports-sustained-growth-in-2021
